Reduces the risk of acquiring infections



Clinical trials have documented that taking LACTOGG®’s probiotic reduces the risk of infections in:

●    Premature and young infants
●    Toddlers and children attending nurseries and daycare centres
●    Children with serious and repeated lung infections
●    Children admitted to hospital
●    Adults in intensive care units
●    Elderly

It has positive effects on immunity by:

●    Boosting immunisations 

Taking LACTOGG®’s probiotic long term offers a way of reducing the risk of being infected.

Furthermore, the beneficial effects of this probiotic strain extend beyond just reducing infection risk. Even when we do become infected we can still make use of the GG probiotic’s positive effects on the immune system to help boost our ability to overcome the infection.

Less infections means less suffering and a lower financial burden for the patient and the family.

The less often we are infected the less we need to take antibiotics. On occasions where the doctor finds it necessary to prescribe antibiotics, taking LACTOGG®’s probiotic strain can also protect us from the side-effects of antibiotics.


How should LACTOGG® be taken?

Babies, children and adults: 

At least 1 capsule or 1 sachet a day

Continue to take LACTOGG® even when infected and throughout the period(s) antibiotics are consumed.




References:

Khailova L. et al. Probiotic administration reduces mortality and improves intestinal epithelial homeostasis in experimental sepsis. Anaesthesiology 2013;119(1):166-177

Kumpu M et al. Recovery of probiotic Lactobacillus rhamnosus GG in tonsil tissue after oral administration: randomised, placebo-controlled,double-blind clinical trial. Br J Nutr 2013;109(12):2240-6

Lu R et al.Isolation, identification, and characterization of small bioactive peptides from Lactobacillus GG conditional media that exert both anti-Gram-negative and Gram-positive bactericidal activity.J Pediatr Gastroenterol Nutr 2009;49(1):23-30

Silva M et al. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987;31(8):1231-1233

Wong S-S et al.Inhibition of Streptococcus pneumoniae adherence to human epithelial cells in vitro by the probiotic Lactobacillus rhamnosus GG. BMC Research Notes 2013;6:135







Hong Kong Special Administrative Region PaediHealth (HK) Ltd. (1286528) 18th Floor, United Centre, 95 Queensway
Hong Kong
Tel: +852 3486 7233     Fax: +852 3486 3723
China Guangzhou Synthgensys Biotechnology Co. Ltd. Unit 501-1, No. 7, Spiral 4 Road, Guangzhou International Bioisland, P R China Tel: +0757 26616888     Fax: +0757 26382288 Brunei Am Prolife Company (P20017787) P.O. Box 31, Jalan Gadong
BE3919, Brunei Darulssalam
Tel: +673 7335566
Email: amprolifebn@gmail.com
Singapore ProbioCare Pte. Ltd. (201603757R) 32 Ean Kiam Place
Singapore 429119
Tel: +65 6255 5592     Fax: +65 6255 5563
Malaysia ProbioCare Sdn. Bhd. (1124987-P) 122 Jalan Ipoh
51200 Kuala Lumpur
Malaysia Tel: +603 2011 1223     Fax: +603 2094 7723

Thailand Paedicare (Thailand) Co. Ltd 973 President Tower, Level 14
Unit D and E (1423) Ploenchit Road, Lumpini,
Pathumwan, Bangkok 10330, Thailand
Tel: +66 99 2828338
FOLLOW US websiteusers@lactogg.com Brochures Privacy Policy Glossary
Copyright 2017-2022 Guangzhou Synthgensys Biotechnology Co.Ltd.